Blood Based Biomarkers Market 2025–2029: Strategic Opportunities and Growth Insights

Uncover key drivers, emerging technologies, and competitive movements shaping the blood based biomarkers market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Blood Based Biomarkers Market Now And By 2029?

The blood based biomarkers market has seen considerable growth over recent years. This market is anticipated to expand from $23.13 billion in 2024 to reach $25.83 billion in 2025, achieving an 11.6% compound annual growth rate (CAGR). Historically, this growth has been driven by factors such as the increasing global prevalence of cancer, the wider acceptance of personalized medicine, greater investment in biomarker research, an expansion of biomarker-involved clinical trials, and more approvals for companion diagnostics.

The blood based biomarkers market is anticipated to experience significant expansion in the coming years. Its size is projected to reach $40.66 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 12.0%. This growth during the forecast period is attributable to the increasing integration of AI and machine learning in biomarker analysis, a heightened demand for early disease detection, the spread of telemedicine and remote diagnostics, the escalating prevalence of chronic diseases, and a growing consumer awareness of health matters. Prominent trends expected within this period include AI-driven biomarker discovery, advancements in liquid biopsy, the integration of multi-omics, the development of point-of-care (POC) testing devices, and innovations in next-generation sequencing (NGS).

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24176&type=smp

Which Long-Term Drivers Are Expected To Sustain The Blood Based Biomarkers Market?

The increasing incidence of cardiovascular diseases is projected to propel the expansion of the blood-based biomarkers market moving forward. These diseases encompass a range of disorders affecting the heart and blood vessels, including conditions such as coronary artery disease, heart failure, and stroke. The surge in cardiovascular diseases is largely attributed to escalating risk factors like unhealthy diets and rising obesity rates. Blood-based biomarkers aid in the diagnosis and monitoring of cardiovascular diseases by providing insights into disease progression, risk assessment, and treatment response through measurable substances found in the blood. For instance, in September 2024, the National Center for Biotechnology Information, a US-based government agency, reported a global health research initiative. Projections indicated a 90% rise in cardiovascular disease prevalence between 2025 and 2050, with anticipated cardiovascular deaths reaching 35.6 million by 2050. Consequently, the escalating cases of cardiovascular diseases are driving the growth of blood-based biomarkers.

How Is The Blood Based Biomarkers Market Classified By Different Segments?

The blood based biomarkers market covered in this report is segmented –

1) By Type: Genetic Biomarkers, Protein Biomarkers, Metabolic Biomarkers, Cell-Based Biomarkers, Epigenetic Biomarkers

2) By Technology: Next-Generation Sequencing, Polymerase Chain Reaction, Immunoassays, Mass Spectrometry, Other Technologies

3) By Application: Cancer, Cardiovascular Diseases, Neurological Diseases, Immunological Diseases, Other Applications

4) By End Users: Hospitals And Clinics, Diagnostic Laboratories, Research And Academic Institutes, Other End Users

Subsegments:

1) By Genetic Biomarkers: Deoxyribonucleic Acid (DNA) Mutations, Ribonucleic Acid (RNA) Expression Profiles, Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Fusions

2) By Protein Biomarkers: Enzymes, Hormones, Cytokines, Tumor Markers, Acute Phase Proteins

3) By Metabolic Biomarkers: Lipid Profiles, Amino Acid Levels, Glucose And Lactate Levels, Organic Acids, Metabolite Panels

4) By Cell-Based Biomarkers: Circulating Tumor Cells (CTCs), Immune Cell Profiling, Stem Cells, Platelets, Endothelial Cells

5) By Epigenetic Biomarkers: Deoxyribonucleic Acid (DNA) Methylation Patterns, Histone Modifications, Non-Coding Ribonucleic Acid (RNA), Chromatin Accessibility, Epigenetic Enzyme Activity

What Current And Upcoming Trends Are Shaping The Blood Based Biomarkers Market?

Leading companies in the blood-based biomarkers market are concentrating on technological advancements like high-accuracy blood biomarker tests to assist physicians in diagnosing Alzheimer’s disease. A high-accuracy blood biomarker test functions as a diagnostic instrument, utilizing specific biomarkers in the blood to detect conditions or monitor health with high precision and reliability. For instance, in October 2023, Quanterix, a US-based life sciences company, introduced LucentAD p-Tau 217, a high-accuracy blood biomarker test designed to help physicians diagnose Alzheimer’s disease (AD) in adults experiencing cognitive impairment. This test measures phosphorylated tau protein at threonine 217 (p-Tau 217), a biomarker closely linked with AD pathology, particularly amyloid accumulation in the brain. The LucentAD p-Tau 217 test achieves over 90% accuracy, satisfying strict diagnostic criteria, and is meant to be used in conjunction with other diagnostic tools rather than independently.

Who Are The Primary Market Leaders In The Blood Based Biomarkers Market?

Major companies operating in the blood based biomarkers market are Siemens Healthineers AG, Agilent Technologies Inc, Eisai Co Ltd, Sysmex Corporation, Exact Sciences Corporation, Guardant Health, Quanterix Corporation, Illumina Inc, QIAGEN NV, GENFIT, Foundation Medicine Inc, Adaptive Biotechnologies Corporation, GRAIL LLC, Biodesix Inc, Cleveland Diagnostics Inc, Creative Diagnostics, Epigenomics AG, C2N Diagnostics, Diadem srl, Proteomedix AG

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/blood-based-biomarkers-global-market-report

Which Regional Markets Are Emerging As Key Centers For The Blood Based Biomarkers Market?

North America was the largest region in the blood-based biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the blood based biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=24176&type=smp

Browse Through More Reports Similar to the Global Blood Based Biomarkers Market 2025, By The Business Research Company

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795